Tag

Michael Kamarck

Panel: Biotech Manufacturing Industrialization, Talent Development, and Leadership — A Tribute to Our Friend Mike Kamarck
LIFE SCIENCES, LIFE SCIENCES, VIDEO

Panel: Biotech Manufacturing Industrialization, Talent Development, and Leadership — A Tribute to Our Friend Mike Kamarck

Over the last few decades we have all witnessed the industrialization of biologics manufacturing, as well as continuous progress in complex medicines such as Cell and Gene Therapy. In this panel we will reflect on where we started, where we are now, and what our future holds. We dedicate this conversation to Mike Kamarck, an exceptional leader of our era whose legacy includes everything we plan to discuss: Alison MooreCMC Executive Dr. Alison Moore is a CMC Executive who most recently served as the Chief Technical Officer at Allogene Therapeutics. Prior to this role, Moore served as Senior Vice President,…

Continue reading
LIFE SCIENCES, LIFE SCIENCES, VIDEO

Panel: Looking Backwards, Looking Forwards: Maximizing Our Impact on the Future of Medicine

The past few years has seen a migration of talent and technology from traditional biopharmaceutical manufacturing to ATMP manufacturing: How has this changed the CMC ecosystem, and are we overbuilding capacity again? Avoiding the dangers of fragmentation. How should we better communicate, collaborate, and consolidate our best ideas so we all succeed? Discussing the reasons to set up a new company today, and imagining how our business ecosystem will continue to grow and evolve Debating which production platforms will best suit the newer modalities Exploring the next steps for existing platforms like mAbs: How do we efficiently serve giant markets…

Continue reading
Panel: Looking Backwards, Looking Forwards —How Did the Last Two Years Change Us?
LIFE SCIENCES, LIFE SCIENCES, VIDEO

Panel: Looking Backwards, Looking Forwards —How Did the Last Two Years Change Us?

How has working through a global pandemic impacted the way we do business? Taking stock of how we changed and why we changed. What are some of the net positives? What are some of the things where we do want to return to how things used to be? Reviewing where our organizations were five years ago and where we planned to be today, how much has COVID-19 changed the trajectory of our journeys? What are some of the lessons learned that we plan to take with us into the future? Is the community of biopharmaceutical manufacturers stronger for this experience?…

Continue reading
COVID-19 MAbs at Pandemic Speed, Volumes and COGs
LIFE SCIENCES, LIFE SCIENCES, VIDEO

COVID-19 MAbs at Pandemic Speed, Volumes and COGs

Vir Biotech has discovered a neutralizing COVID-19 mAb to a unique, highly conserved Coronavirus spike sequence, high barrier to resistance and effector function We have partnered with numerous CDMOs and GSK to move from discovery to the clinic in approximately 6 months World-wide pandemic requirements for an efficacious neutralizing mAb may exceed 20 metric tons – challenging the capacity of industry manufacturing infrastructure — Michael Kamarck Chief Technology Officer Vir Biotechnology Michael Kamarck is Chief Technology Officer at Vir. Previously, he was senior vice president of Global Vaccines and Biologics Manufacturing and president of Merck BioVentures where he was responsible…

Continue reading
LIFE SCIENCES, LIFE SCIENCES, VIDEO

Keynote: The Successful History of Biologics Manufacturing Provides Foresights and Strategies for New Bio Modalities

Establishment of broad communities of practitioners in both manufacturing and process development accelerated maturation of both disciplines Convergence of these process and manufacturing technologies was driven by excellence and capacity in selected CMOs Manufacturing portability has provided remarkable stories of win-win capacity-exchange between proprietary companies Process convergence has resulted in remarkable progress in process yields and cost improvement Intro to Vir Bio: Capacity and cost improvements in bio-manufacturing facilitate global access to medicines for Infectious Disease — Michael Kamarck Chief Technology Officer Vir Biotechnology Michael Kamarck is Chief Technology Officer at Vir. Previously, he was senior vice president of Global…

Continue reading